Understanding how VPS72 affects immune cells in tumors
VPS72 controls Treg cell stability and adaptation to tumor microenvironment
This study is looking at a protein called VPS72 to see how it affects certain immune cells that help control the body's response to tumors, and by understanding this better, we hope to find new ways to improve cancer treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10931580 on NIH RePORTER |
What this research studies
This research investigates the role of VPS72, a protein that influences the behavior of regulatory T cells (Tregs) within the tumor microenvironment. By studying mouse models, the researchers aim to uncover how VPS72 contributes to Treg stability and function, which are crucial for the immune system's ability to respond to tumors. The approach involves advanced techniques to analyze gene expression and chromatin remodeling, providing insights into the mechanisms that allow tumors to evade immune detection. Patients may benefit from a deeper understanding of Treg behavior in cancer, potentially leading to improved therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that exhibit immune evasion, particularly those where Treg activity is suspected to play a role.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not involve Treg interactions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing the immune response against tumors, improving cancer treatment outcomes.
How similar studies have performed: Previous research has shown promising results in understanding Treg dynamics in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
East Lansing, United States
- Henry Ford Health + Michigan State University Health Sciences — East Lansing, United States (Active)
Researchers
- Principal investigator: Mi, Qing-Sheng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Mi, Qing-Sheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.